康希诺生物-B(06185.HK)澄清新型疫苗三期临床试验尚未入组
康希诺生物-B(06185.HK)公布,注意到公司股票价格波动,以及部分媒体有关重组新型冠状病毒疫苗(腺病毒载体)(「Ad5-nCoV」)进展的报道。
康希诺作出澄清及声明,公司於今年8月11日收到「一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗」的授予发明专利权通知书。该专利由中国人民解放军军事科学院军事医学研究院与公司联合申请;及Ad5-nCoV的二期临床试验已完成。公司目前正在与多个国家联系,计划尽快推动Ad5-nCoV国际多中心三期临床试验。截至目前,Ad5-nCoV的三期临床试验尚未入组。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.